6 Best Peptides for Endometriosis

What to Know Before Choosing a Peptide for Endometriosis

Endometriosis sits at the intersection of chronic inflammation, immune dysfunction, hormonal signaling, and tissue damage. That complexity is part of why people are looking beyond standard treatment options toward peptides that work on some of the underlying mechanisms, including the inflammatory cytokines that sustain lesion activity, the immune evasion that lets ectopic tissue survive, and the fibrotic changes that drive adhesion formation and pain.

Every compound in this guide earned its place by one standard: people are using it or actively discussing using it for endometriosis. That includes compounds with no regulatory approval anywhere, compounds prescribed off-label through functional medicine practitioners, and one compound that has just cleared FDA authorization to begin its first human trial. Evidence strength varies enormously across this list, and that variation is stated honestly inside each entry rather than used as a reason to exclude any compound. A widely discussed compound with thin evidence belongs here with its evidence described plainly. A compound with only community-reported use belongs here too.

The numbers in front of each entry give the list a spine and reflect how prominently each compound appears in the research and in real-world community use. They are not a ranking of one compound as better than another for you. The right choice depends on your specific situation, what stage of the condition you are managing, what other treatments you are using, and what you build with a personalized plan.

1. BPC-157: For Inflammation and Pelvic Pain

BPC-157 stands for Body Protection Compound-157, a synthetic pentadecapeptide, meaning a chain of fifteen amino acids, originally derived from a protein found in gastric juice. It is the most studied research peptide for endometriosis and the only one with a published exploratory human trial specifically for this condition.

Endometriosis pain has several overlapping drivers: the chronic inflammatory state inside the pelvis, elevated levels of signaling molecules like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) that keep local inflammation running, and the pathological growth of new blood vessels that feed lesion tissue. BPC-157 has been studied for its effects on all three. It appears to work in part by modulating NF-kB, which functions as a master transcription factor, essentially the switch that activates a wide range of inflammatory gene programs. Reducing that signal dampens the downstream cascade of pro-inflammatory molecules that characterize active endometriosis.

The compound also appears to influence natural killer (NK) cell activity. NK cells are the immune system's surveillance units, the cells that would normally identify and destroy ectopic endometrial tissue. Deficient NK cell function is one of the hallmarks of endometriosis pathology, which makes BPC-157's potential to restore some of that surveillance capacity a specific mechanistic argument for its relevance to this condition rather than just a general anti-inflammatory effect.

The human evidence here is real but limited. An exploratory open-label pilot published in 2023 enrolled 18 women with Stage II to III endometriosis and ran a twelve-week protocol. Participants showed meaningful reductions on standardized pain scales and reduced serum IL-6 levels by the end of the study. Those are clinically relevant findings. The study also has significant limitations: 18 participants is a small sample, there was no control group, and no larger Phase 2 study has followed. It remains the only published human trial of any research peptide specifically for endometriosis, which makes it the strongest starting point in the research-peptide space while also illustrating how early that space still is.

Community use of BPC-157 for endometriosis is considerably wider than the published literature. Across forums and dedicated endometriosis communities, women report using it primarily for pain reduction. The most common pattern is combining it with TB-500, addressed in the next entry, for what users describe as complementary anti-inflammatory and tissue-repair effects. Some users report substantial pain relief; others report minimal change. That range is consistent with a compound that has real mechanistic relevance, one small human trial, and a broader body of preclinical data behind it.

2. TB-500: For Adhesion Formation and Tissue Repair

TB-500 is a synthetic analog of Thymosin Beta-4, a protein that occurs naturally in the body and plays a role in how tissue responds to injury. Where BPC-157 is primarily discussed for its anti-inflammatory effects, TB-500 is used for what happens structurally after inflammation: the adhesion formation and fibrotic scarring that are a major source of pain and organ dysfunction in endometriosis.

Adhesions are bands of scar tissue that form when the body tries to heal damaged surfaces. In endometriosis, the chronic inflammation and repeated tissue injury in the pelvic cavity create conditions where adhesions develop around the ovaries, fallopian tubes, bowel, and bladder. TB-500's primary studied mechanism in this context is anti-fibrotic activity, meaning it appears to reduce the signaling that drives scar tissue formation. In animal models, it has been shown to reduce adhesion formation after surgical intervention and to improve tissue healing markers in damaged tissue.

No human clinical trials exist for TB-500 in endometriosis. The evidence for this application is drawn from animal models and from the broader tissue-repair literature, where TB-500 has a more established record. What drives its use in the endometriosis community is largely the logic of pairing it with BPC-157: the two compounds address different parts of the problem, with BPC-157 targeting the inflammatory environment and TB-500 targeting the structural consequences. This combination is by far the most commonly mentioned research peptide protocol in endometriosis community discussions.

The honest position on the evidence: mechanistically relevant, well-represented in community use, and without the human trial data that would let us say more with confidence. Users across multiple forums report the combination as more effective than BPC-157 alone for managing both pain and the physical symptoms associated with adhesions, but this is community-reported experience rather than anything measured in controlled research.

3. Thymosin Alpha-1: For Immune Surveillance

Thymosin Alpha-1, sometimes written TA1 or T-alpha-1, is a synthetic version of a peptide the thymus gland produces naturally. The thymus trains and matures immune cells, particularly T-cells, which coordinate immune surveillance and targeted immune responses. Thymosin Alpha-1 is approved in several countries for hepatitis and immunodeficiency conditions, where its immunomodulatory effects are the primary therapeutic target.

For endometriosis, the rationale is specific rather than general. One of the defining features of the condition is that ectopic endometrial tissue survives outside the uterus in part because the immune system fails to clear it. NK cells, which should recognize and destroy tissue that does not belong, show reduced activity in women with endometriosis. T-cell surveillance is similarly impaired. The peritoneal environment around the lesions has properties that resist the immune responses that would normally eliminate abnormal tissue.

Thymosin Alpha-1 works by activating dendritic cells, which are the antigen-presenting cells that initiate immune responses, enhancing NK cell cytotoxicity, and promoting a Th1 immune pattern, which is the pattern associated with active cell-mediated immunity rather than tolerance. These are precisely the immune functions that are suppressed in endometriosis, which makes the mechanistic case for Thymosin Alpha-1 unusually direct for a compound that has not been tested in dedicated clinical trials for this condition.

No large-scale human trial has been completed for Thymosin Alpha-1 in endometriosis as of 2026. What exists is strong immunological reasoning, extrapolation from its approved uses in immune conditions, and inclusion in multi-peptide protocols by functional medicine practitioners working in this space. It is typically not used alone; most protocols pair it with BPC-157 or other compounds addressing inflammation and tissue repair. A specific caution applies here: compounds that activate the immune system can potentially exacerbate autoimmune-like conditions, and endometriosis shares some features with autoimmune disease. Qualified oversight rather than self-directed use is important for this one in particular.

4. GHK-Cu: For the Peritoneal Environment

GHK-Cu, which stands for glycine-histidine-lysine copper, is a naturally occurring copper-binding tripeptide, a chain of three amino acids, found in human plasma. It declines with age and is perhaps best known in skin and cosmetic research for its effects on collagen synthesis, antioxidant activity, and tissue remodeling.

Its relevance to endometriosis is more specific than its general tissue-repair reputation suggests. The peritoneum, the membrane lining the pelvic cavity, is damaged by endometriotic lesions and the chronic inflammation they sustain. That damage affects the microenvironment in which lesions grow and in which the immune system operates. GHK-Cu's studied effects on collagen remodeling and oxidative stress are relevant here because both processes contribute to adhesion formation and to the structural recovery of damaged peritoneal tissue.

Research has also associated GHK-Cu with improved endometrial receptivity markers, which is relevant for people dealing with endometriosis-related infertility. Endometrial receptivity refers to how receptive the uterine lining is to implantation, and it is often reduced in endometriosis. The association here is at the level of markers and mechanistic research rather than clinical outcomes from trials.

No human clinical trials have been completed for GHK-Cu specifically in endometriosis. It appears in community protocols and practitioner-designed multi-peptide stacks, typically alongside BPC-157 and TB-500, positioned as addressing peritoneal tissue quality and endometrial receptivity rather than inflammation directly. The evidence is preclinical and mechanistic. Its place in community discussion is genuine but quieter than the compounds above it on this list.

5. KPV: For Localized Anti-Inflammatory Support

KPV is a tripeptide made up of lysine, proline, and valine. It is the C-terminal fragment of alpha-MSH, short for alpha-melanocyte-stimulating hormone, a naturally occurring signaling molecule with known anti-inflammatory properties. KPV is the segment of that molecule where those anti-inflammatory effects are concentrated.

Its mechanism in the endometriosis context is localized anti-inflammatory signaling through melanocortin receptors. The pathway it targets overlaps meaningfully with BPC-157: both compounds appear to modulate NF-kB, the master inflammatory transcription factor described in the first entry. This gives KPV a theoretical basis for reducing the cytokine environment that sustains endometriotic lesion activity, working through a distinct receptor pathway from BPC-157 rather than redundantly through the same one. That distinction is the argument for including it in a multi-compound protocol rather than treating it as a substitute.

Community discussion of KPV for endometriosis pain exists but is limited. It appears in forum threads alongside BPC-157, typically cited for pain relief with positive reports from individual users. No clinical trial data exists for this use as of 2026. The evidence here is mechanistic and user-reported, without the animal model record that TB-500 and GHK-Cu carry in adjacent applications. For anyone building a protocol, KPV represents an option with a coherent anti-inflammatory mechanism and real community mention, but a thinner base of supporting evidence than the compounds ranked above it.

6. ENDO-205: A Non-Hormonal Peptide Entering Human Trials

ENDO-205 is different from every other compound on this list in one important way: it is the first non-hormonal peptide therapeutic for endometriosis to receive FDA authorization to begin human clinical testing. That authorization, an Investigational New Drug (IND) clearance, was granted in March 2026. It is not approval to treat patients. It is authorization to begin Phase 1 safety trials in healthy pre-menopausal women. The compound is not available through any clinic, telehealth platform, or research chemical channel for patient use.

It belongs on this list because it is generating substantial discussion in endometriosis communities and represents the direction the most serious research in the field is heading. Understanding what it is and what stage it occupies matters for anyone following the space.

ENDO-205 is described as first-in-class because its mechanism is fundamentally different from existing hormonal treatments. Rather than suppressing estrogen to starve lesions of their growth signal, it targets the Wnt/beta-catenin pathway, a cellular signaling pathway that controls cell proliferation, movement, and survival. In endometriosis, this pathway is dysregulated in lesion tissue. The peptides in ENDO-205 bind to beta-catenin, preventing it from moving into the cell nucleus where it would activate the genes driving lesion growth. The compound uses a pH-sensitive delivery mechanism designed to activate preferentially in the acidic microenvironment of diseased tissue rather than throughout the body.

In animal models, ENDO-205 eliminated lesions and inflammation without the hormonal side effects associated with current treatments. No safety signals appeared in preclinical toxicology studies. Phase 1 is focused on safety and tolerability in healthy participants, not on measuring efficacy in people with endometriosis. Phase 2 and Phase 3 trials, where efficacy would be established, are years away. Its relevance to a practical protocol decision today is zero. Its relevance to understanding where the field is heading is high, and the community interest is real enough that omitting it would leave a meaningful gap in this guide.

How These Peptides Compare

Frequently Asked Questions

Are peptides for endometriosis legal to obtain?

The answer depends on which compound. GnRH-based pharmaceutical peptides like elagolix (Orilissa) are FDA-approved for endometriosis and require a prescription from a licensed provider. Research peptides including BPC-157, TB-500, Thymosin Alpha-1, GHK-Cu, and KPV are not FDA-approved for this condition and occupy a legal gray area in the United States: they are not controlled substances, but they are not approved for human therapeutic use, and their availability and legality varies by source and jurisdiction. ENDO-205 has received FDA authorization to begin clinical trials only and is not available for patient use outside of those trials.

How do people typically access research peptides for endometriosis?

Two main routes exist. Compounding pharmacies working with a prescribing practitioner, usually in functional or integrative medicine, represent the route with the most quality assurance, since compounding pharmacies operate under pharmacy regulations and a supervising practitioner provides guidance and monitoring. Research chemical suppliers are the other route, with considerably more variation in quality and less oversight. The underlying compound may be the same; the chain of custody and independent verification are not.

Do any of these peptides address endometriosis pain without suppressing hormones?

Among research peptides, BPC-157, TB-500, KPV, and GHK-Cu all work through non-hormonal mechanisms targeting inflammation, immune function, and tissue repair rather than estrogen signaling. The approved hormonal treatments have a much stronger clinical evidence base, but their side effects related to estrogen suppression lead some people to explore alternatives. ENDO-205 is being developed as a non-hormonal, lesion-targeting option, but it is years away from any approval. Non-hormonal research peptide options exist and are being used, though none carries the clinical validation of the approved hormonal treatments.

Is combining multiple peptides for endometriosis common?

Yes. The BPC-157 plus TB-500 combination is by far the most commonly reported approach in community protocols, with the two compounds positioned as addressing different aspects of the condition. Some protocols add Thymosin Alpha-1 for immune support or GHK-Cu for peritoneal tissue quality. Multi-peptide approaches make mechanistic sense given how many different pathways endometriosis involves, but they also increase complexity and the importance of qualified oversight, since interactions between compounds in this context have not been studied in controlled research.

What should someone with endometriosis discuss with their doctor before using research peptides?

The most important questions involve how research peptide use might interact with any current hormonal treatment, whether there are specific contraindications given individual health history, and what monitoring would be useful during use. Anyone with a history of cancer, active autoimmune conditions, or who is pregnant or planning to conceive should raise those specifically, since each carries distinct considerations for several compounds on this list. A practitioner familiar with both endometriosis management and peptide pharmacology is a different resource than a standard provider who may have limited exposure to off-label research compound use.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for endometriosis in one place.